Therapeutic strategies for pulmonary sarcoidosis

References

• James WE, Koutroumpakis E, Saha B, et al. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest. 2018 Aug;154(2):349–356.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 Nov;164(10):1885–1889.
   PubMed Web of Science ®Google Scholar
• Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017;132:9–14.
   PubMed Web of Science ®Google Scholar
• Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015 Apr;109(4):526–531.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Wells AU. The indications for the treatment of sarcoidosis: Well’s Law. Sarcoidosis Vasc Diff Lung Dis. 2017;34:280–284.
   PubMed Web of Science ®Google Scholar
• Moller DR. Pulmonary fibrosis of sarcoidosis. New approaches, old ideas. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S37–S41.
   PubMed Web of Science ®Google Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018 Oct;4(4):1–3.
   PubMedGoogle Scholar
• Judson MA Quality of Life in Sarcoidosis. Seminars in respiratory and critical care medicine. Vol. 38; 2017 Aug. p. 546–558.
   Google Scholar
• Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007 Nov-Dec;10(Suppl 2):S125–37.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
   PubMed Web of Science ®Google Scholar
• Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005 Jun;28(2):212–232.
   PubMed Web of Science ®Google Scholar
• Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002 Dec;83(Suppl 12):S10–7.
   PubMed Web of Science ®Google Scholar
• Victorson DE, Cella D, Judson MA. Quality of life evaluation in sarcoidosis: current status and future directions. Curr Opin Pulm Med. 2008 Sep;14(5):470–477.
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010 Jan;339(1):1–4.
   PubMed Web of Science ®Google Scholar
• Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. Expert Rev Clin Immunol. 2016 ;12(11):1191–1208.
   PubMed Web of Science ®Google Scholar
• Nunes H, Uzunhan Y, Gille T, et al. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J. 2012 Sep;40(3):750–765.
   PubMed Web of Science ®Google Scholar
• Judson MA, Gilbert GE, Rodgers JK, et al. The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology (Carlton, Vic). 2008 Jan;13(1):97–102.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Crommelin HA, Deneer VHM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015 Jul;46(1):175–185.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J. 2013 Jun;41(6):1424–1438.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Brynedal B, Darlington P, et al. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respir Res. 2010;11:25.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004 Mar;125(3):997–1004.
   PubMed Web of Science ®Google Scholar
• Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008 Feb;177(3):330–336.
   PubMed Web of Science ®Google Scholar
• Mañá J, Gómez-Vaquero C, Montero A, et al. Löfgren’s syndrome revisited: a study of 186 patients. Am J Med. 1999 Sep;107(3):240–245.
   PubMed Web of Science ®Google Scholar
• Rybicki B, Major M, Popovich J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. American Journal of Epidemiology. 1997;145(3):234–241.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994 Apr;149(4):893–898.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010 May;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979 Aug;60(4):215–221.
   PubMedGoogle Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996 Mar;51(3):238–247.
   PubMed Web of Science ®Google Scholar
• Judson M. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. CHEST. 1999;115(4):1158–1165.
   PubMed Web of Science ®Google Scholar
• Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis. 1993 Jun;147(6_pt_1):1598–1600.
   PubMedGoogle Scholar
• Broos CE, Wapenaar M, Looman CWN, et al. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. Eur Respir J. 2018 01;51(1):1–4.
   Web of Science ®Google Scholar
• Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med. 2018;05:S31–S37.
   Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997 Mar;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002 Jan;121(1):24–31.
   PubMed Web of Science ®Google Scholar
• Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 1987 Sep;87(9):496–499.
   PubMedGoogle Scholar
• James DG, Carstairs LS, Trowell J, et al. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967 Sep;2(7515):526–528.
   PubMed Web of Science ®Google Scholar
• Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973 Apr;107(4):609–614.
   PubMed Web of Science ®Google Scholar
• Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005 Apr;(2):CD001114:1–58.
   Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000 Mar;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52(208):525–533.
   PubMedGoogle Scholar
• Korsten P, Strohmayer K, Baughman RP, et al. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016 Mar;23(2):67–75.
   PubMedGoogle Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013 Sep;144(3):805–812.
   PubMed Web of Science ®Google Scholar
• Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002 Sep;8(5):470–476.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr;155(8):846–851.
   PubMedGoogle Scholar
• Vorselaars AD, van Moorsel CH, Zanen P, et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med. 2015 Feb;109(2):279–285.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Ainslie GM, Bateman ED, Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999 Mar; 16(1):87–92.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. 1990 Mar;299(3):153–157.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014 Apr;43(5):613–626.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Mar;21(1):43–48.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011 Nov;38(5):1145–1150.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssén A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014 Nov;108(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006 Oct;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006 Oct;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014 Jan;108(1):189–194.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar Inflectra. Respir Med. 2018 May;138S:S7–S13.
   PubMedGoogle Scholar
• Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week Trial of Adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr;31(1):46–54.
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012 Oct;6(4):238–247.
   PubMed Web of Science ®Google Scholar
• Gupta D, Agarwal R, Aggarwal AN, et al. Immune responses to mycobacterial antigens in sarcoidosis: a systematic review. Indian J Chest Dis Allied Sci. 2011 Jan-Mar;53(1):41–49.
   PubMedGoogle Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Nov;44(5):1296–1307.
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003 Jul;124(1):177–185.
   PubMed Web of Science ®Google Scholar
• Ng S, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014;89(3):355–360.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Barney JB, O’Hare L, et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017 Jun;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.
   PubMedGoogle Scholar
• Krause ML, Cooper LT, Chareonthaitawee P, et al. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016 Jan;55(1):189–191.
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Wyser CP, van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med. 1997 Nov;156(5):1371–1376.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013 Aug;10(4):362–370.
   PubMedGoogle Scholar
• Judson MA. Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. Expert Rev Respir Med. 2017. 02. 11(2):111–118.
   PubMed Web of Science ®Google Scholar
• Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011 Dec;38(6):1368–1373.
   PubMed Web of Science ®Google Scholar
• Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018. 01. 153(1):105–113.
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006 Jan;61(1):68–74.
   PubMed Web of Science ®Google Scholar
• Zhang C, Chan KM, Schmidt LA, et al. Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis. Chest. 2016 Feb;149(2):499–507.
   PubMed Web of Science ®Google Scholar
• Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med. 2012 Jan;37(1):21–25.
   PubMed Web of Science ®Google Scholar
• Xu L, Kligerman S, Burke A. End-stage sarcoid lung disease is distinct from usual interstitial pneumonia. Am J Surg Pathol. 2013 Apr;37(4):593–600.
   PubMed Web of Science ®Google Scholar
• Judson M, Boan A, Lackland D. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diff Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017 10;50(4):1–11.
   Web of Science ®Google Scholar
• Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013 May;68(5):436–441.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;10;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Hansell DM, Milne DG, Wilsher ML, et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology. 1998 Dec;209(3):697–704.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013 Dec;107(12):2009–2013.
   PubMed Web of Science ®Google Scholar
• Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2013 Mar;41(3):621–626.
   PubMed Web of Science ®Google Scholar
• Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest. 1984 Oct;86(4):585–588.
   PubMed Web of Science ®Google Scholar
• Panjabi C, Sahay S, Shah A. Aspergilloma formation in cavitary sarcoidosis. J Bras Pneumol. 2009 May;35(5):480–483.
   PubMed Web of Science ®Google Scholar
• Uzunhan Y, Nunes H, Jeny F, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2017 Jun;49(6):1–13.
   PubMed Web of Science ®Google Scholar
• Kravitz JN, Berry MW, Schabel SI, et al. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest. 2013 May;143(5):1414–1421.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2016 08;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest. 1987 Sep;92(3):505–508.
   PubMedGoogle Scholar
• Shin B, Koh WJ, Shin SW, et al. Outcomes of bronchial artery embolization for life-threatening hemoptysis in patients with chronic pulmonary aspergillosis. PLoS One. 2016;11(12):e0168373.
   PubMed Web of Science ®Google Scholar
• Corr P. Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization. Cardiovasc Intervent Radiol. 2006 Sep-Oct;29(5):807–810.
   PubMed Web of Science ®Google Scholar
• Kasprzyk M, Pieczyński K, Mania K, et al. Surgical treatment for pulmonary aspergilloma - early and long-term results. Kardiochir Torakochirurgia Pol. 2017 Jun;14(2):99–103.
   PubMedGoogle Scholar
• Brik A, Salem AM, Kamal AR, et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg. 2008 Oct;34(4):882–885.
   PubMed Web of Science ®Google Scholar
• Tom LM, Palevsky HI, Holsclaw DS, et al. Recurrent bleeding, survival, and longitudinal pulmonary function following bronchial artery embolization for hemoptysis in a U.S. adult population. J Vasc Interv Radiol. 2015 Dec;26(12):1806–13.e1.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003 Sep;124(3):922–928.
   PubMed Web of Science ®Google Scholar
• Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006 May;129(5):1246–1252.
   PubMed Web of Science ®Google Scholar
• Damuth TE, Bower JS, Cho K, et al. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest. 1980 Dec;78(6):888–891.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010 Nov;138(5):1078–1085.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009 Jun;135(6):1455–1461.
   PubMed Web of Science ®Google Scholar
• Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006 Nov;130(5):1481–1488.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):110–120.
   PubMed Web of Science ®Google Scholar
• Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011 Oct;28(2):139–145.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014 Apr;145(4):810–817.
   PubMed Web of Science ®Google Scholar
• Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008 Mar;27(3):329–334.
   PubMed Web of Science ®Google Scholar
• Drent M, Strookappe B, Hoitsma E, et al. Consequences of Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):727–737.
   PubMed Web of Science ®Google Scholar
• van Helmondt SJ, Polish LB, Judson MA, et al. Patient perspectives in sarcoidosis. Curr Opin Pulm Med. 2019 Sep;25(5):478–483.
   PubMed Web of Science ®Google Scholar
• Pilzak K, Żebrowska A, Sikora M, et al. Physical functioning and symptoms of chronic fatigue in sarcoidosis patients. Adv Exp Med Biol. 2018;1040:13–21.
   PubMed Web of Science ®Google Scholar
• Naz I, Ozalevli S, Ozkan S, et al. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. J Cardiopulm Rehabil Prev. 2018 Mar;38(2):124–130.
   PubMed Web of Science ®Google Scholar
• Lingner H, Buhr-Schinner H, Hummel S, et al. Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study. Respiration. 2018;95:343–353.
   PubMed Web of Science ®Google Scholar
• Strookappe B, Swigris J, De Vries J, et al. Benefits of physical training in sarcoidosis. Lung. 2015 Oct;193(5):701–708.
   PubMed Web of Science ®Google Scholar
• Sgalla G, Cerri S, Ferrari R, et al. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. BMJ Open Respir Res. 2015;2(1):e000065.
   PubMed Web of Science ®Google Scholar
• Ekman I, Kjellström B, Falk K, et al. Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. Eur J Heart Fail. 2011 Sep;13(9):1000–1005.
   PubMed Web of Science ®Google Scholar
• Hayama Y, Inoue T. The effects of deep breathing on ‘tension-anxiety’ and fatigue in cancer patients undergoing adjuvant chemotherapy. Complement Ther Clin Pract. 2012 May;18(2):94–98.
   PubMedGoogle Scholar
• Nield M. Dyspnea self-management in African Americans with chronic lung disease. Heart Lung. 2000 Jan-Feb;29(1):50–55.
   PubMed Web of Science ®Google Scholar
• Saketkoo L, Young J, Adell R, et al. Perceptions of A modified mindfulness training (mt) program in sarcoidosis. Am J Respir Crit Care Med. 2016;193:A2688.
   Web of Science ®Google Scholar
• Lal C, Medarov BI, Judson MA. Interrelationship between sleep-disordered breathing and sarcoidosis. Chest. 2015 Oct;148(4):1105–1114.
   PubMed Web of Science ®Google Scholar
• Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008 Sep-Oct;30(5):441–445.
   PubMed Web of Science ®Google Scholar
• Hendriks C, Drent M, De Kleijn W, et al. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study. Respir Med. 2018;05:S24–S30.
   Google Scholar
• Zhou T, Casanova N, Pouladi N, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017 06;7(1):4237.
   PubMedGoogle Scholar
• Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018 12;379(26):2540–2546.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004 Dec;170(12):1324–1330.
   PubMed Web of Science ®Google Scholar
• Rivera NV, Patasova K, Kullberg S, et al. A gene-environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis. Sci Rep. 2019 Dec;9(1):18633.
   PubMedGoogle Scholar
• Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep;5(8):381–387.
   PubMedGoogle Scholar